Evidence map›Paper›PMID 12357368›Full record

ArticleLeukemia2002

Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein-Barr virus infection. A different subtype of AILD-TL?

C Lome-Maldonado, D Canioni, O Hermine, E Delabesse, D Damotte, E Raffoux, P Gaulard, E Macintyre, N Brousse, French Groupe d'Etude des Lymphomes de l'Adulte (GELA)

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00169156 (Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00169156 phase2completednot on this mapstarted 2005, after this paper: background citation

Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab (R-CHOP) in Patients Aged 60 to 80 Years With Previously Untreated T-cell Angioimmunoblastic Lymphoma (AIL).

TypeinterventionalSponsorLymphoma Study AssociationRan2005 to 2012Enrolled27ConditionsUntreated T-cell Angioimmunoblastic LymphomaArmsRituximab, Prednisone, Doxorubicine, Cyclophosphamide, Vincristine
3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Molecular genetics of peripheral T-cell lymphomas.International journal of hematology · 2014
    Review
  5. Angioimmunoblastic T-cell lymphoma partially obscured by an Epstein-Barr virus-negative clonal plasma cell proliferation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

C Lome-MaldonadoDepartment of Pathology (EA 219, University Paris V), Hôpital Necker-Enfants Malades, France.
D Canioni
O Hermine
E Delabesse
D Damotte
E Raffoux
P Gaulard
E Macintyre
N Brousse
French Groupe d'Etude des Lymphomes de l'Adulte (GELA)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We studied eight patients with characteristic features of angio-immunoblastic T cell lymphoma (AILD-TL) associated with more than 25% of large B cells. Polymerase chain reaction (PCR) analysis showed a clonal rearrangement of the T cell receptor (TCR)-gamma chain gene in all cases. One additional case showed a clonal rearrangement of the TCR-beta chain gene by Southern blot hybridization. PCR analysis showed a clonal immunoglobulin rearrangement in three cases presenting with more than 50% of large B cells whereas the other cases had a germline configuration. In 6/8 cases, double-labeling immunohistochemistry and in situ hybridization demonstrated that Epstein-Barr virus (EBV) was mostly present in the large B cells but also detected in some T cells. We further evaluated the frequency of AILD-TL with more than 25% of large B cells in the 106 cases collected by the French GELA group and found an incidence of 18%. The outcome of these patients did not differ significantly from those with less than 25% of B cells. With this approach we confirm the heterogeneity of AILD-TL features and the possible association with a substantial numbers of CD20(+), EBV(+) large B cells. We propose to denominate these cases as 'AILD-TL rich in large B cells' and to consider them as a different entity which can be misdiagnosed as a reactive process or as T cell rich B cell lymphoma.

Indexed as

AgedAged, 80 and overBlotting, SouthernB-LymphocytesEpstein-Barr Virus InfectionsFemaleGene Rearrangement, T-LymphocyteHumansImmunohistochemistryLymphoma, Large-Cell, ImmunoblasticMaleMiddle AgedPolymerase Chain ReactionReceptors, Antigen, T-Cell, gamma-deltaReceptors, Antigen, T-Cell, gamma-delta

Identifiers

PMID12357368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.